GlassScriptPhysician profile
Jessica E Mccabe
NPI 1982961827
$3,490.14
in general payments reported to CMS, 2019-2025
32 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $488 · 2021: $446 · 2022: $743 · 2023: $330 · 2024: $453 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,235.05 | 2019-2022 | |
| Merz North America, INC. | $788.05 | 2020-2025 | |
| Abbvie INC. | $370.14 | 2024-2025 | |
| Spr Therapeutics, INC | $172.07 | 2020 | |
| Arbor Pharmaceuticals, INC. | $111.13 | 2021 | |
| Azurity Pharmaceuticals, INC. | $93.48 | 2024-2025 | Horizant |
| Neurelis, INC. | $63.22 | 2022-2025 | Valtoco |
| Pfizer INC. | $46.71 | 2024-2025 | |
| Sk Life Science, INC. | $46.21 | 2020-2022 | |
| Ucb, INC. | $44.21 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $43.82 | 2024 | Purified Cortrophin Gel |
| Abbott Laboratories | $40.70 | 2019-2021 | |
| Biogen, INC. | $38.28 | 2022-2025 | Vumerity |
| Greenwich Biosciences, INC. | $37.42 | 2019-2020 | |
| Lilly USA, LLC | $33.96 | 2022-2024 | Emgality |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $30.51 | 2024 | Austedo Xr |
| Banner Life Sciences, LLC | $26.96 | 2023 | |
| Boston Scientific Corporation | $23.28 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $21.81 | 2020 | |
| Alexion Pharmaceuticals, INC. | $21.19 | 2024 | Ultomiris |
| Microtransponder, INC. | $20.85 | 2024 | |
| Coherus Oncology, INC. | $20.66 | 2020 | |
| Avion Pharmaceuticals | $18.00 | 2023 | Dhivy |
| Jazz Pharmaceuticals INC. | $17.87 | 2022 | |
| Janssen Biotech, INC. | $17.79 | 2025 | |
| Cycle Pharmaceuticals INC | $17.48 | 2024 | Tascenso Odt |
| Grt US Holding, INC. | $16.16 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.98 | 2022 | |
| Mdd US Operations, LLC | $15.61 | 2022 | |
| Assertio Therapeutics, INC. | $15.21 | 2020 | |
| Allergan, INC. | $13.19 | 2020 | |
| Grifols USA, LLC | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.